Q-omics provides the consensus-scored PNMA8C profile across patient tissues and cancer cell-line models. PNMA8C expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, PNMA8C is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PNMA8C RNA expression shows 11,728 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ESCA, COAD, and GBM as cancer lineages where PNMA8C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNMA8C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNMA8C survival associations across molecular data types. PNMA8C RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNMA8C RNA expression–survival associations across cancer types. High PNMA8C expression shows unfavorable associations in ESCA, STAD and COAD, but favorable associations in SKCM, BRCA and OV. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .031). Together, the overview and detailed table identify ESCA as the clearest survival context for PNMA8C RNA expression.
This table summarizes PNMA8C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PNMA8C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNMA8C shows lower tumor expression in COAD, UCEC, LUSC, BRCA, LUAD and KICH. The COAD box plot shows higher PNMA8C RNA expression in normal versus tumor tissue (log2 FC = −0.308, t-test p < 0.001).
This table shows molecular features associated with PNMA8C in patient tissues and cancer cell lines. In patient samples, PNMA8C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNMA8C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
